Warsaw, Poland – Medicalgorithmics, a global healthcare technology company, is pleased to announce signing of a letter of intent with a leading US-based health monitoring company which offers its monitoring services across North America (the name of the partner will be released as soon as it is allowed by the current contractual obligations of the new partner). This collaboration aims to integrate Medicalgorithmics’ cutting-edge AI-powered software with the company’s wearable biosensors, resulting in enhanced health monitoring capabilities, and it is part of the new US business strategy of Medicalgorithmics introduced at the point of investment by BioFund in Q4, 2022
This agreement sets the stage for expanding the collaboration between the two companies, encompassing technological advancements, software licensing, and distribution partnerships. The primary focus of this partnership will be the seamless integration of Medicalgorithmics’ software platform (PC Client) and its AI-powered analytical package (TechBot) with the US partner’s wearable biosensors. This integration will bring about enhanced product functionality, benefiting patients with cardiac conditions. Additionally, the collaboration envisions joint efforts in developing remote screening and monitoring services.
In the ever-expanding landscape of artificial intelligence (AI) and its crucial role in electrocardiogram data analysis, Medicalgorithmics’ software platform and predictive analytics capabilities provide the US partner with a unique opportunity to differentiate its cardiac monitoring product line. This collaboration, complemented by other recently announced and ongoing initiatives, showcases a shared dedication to creating AI-based solutions that empower healthcare professionals to improve patient outcomes while streamlining workflows and reducing costs.
“The collaboration between Medicalgorithmics and our new US partner signifies the tremendous potential to enhance the quality and efficiency of ECG data analysis through the application of AI. Not only are we well-positioned to compete independently, but we are also eager to form broad partnerships and share our expertise with others. By leveraging AI, we have developed a scalable and state-of-the-art ecosystem for cardiac diagnostics, combining our proprietary algorithms, software, and devices that enable physicians to make more informed decisions in their diagnoses. We are now excited to extend this opportunity to new partners in the US, as demonstrated by this integration LOI, which will bring benefits to both companies by enhancing diagnostics capabilities,” commented Jarosław Jerzakowski, Chief Commercial Officer of Medicalgorithmics.
Medicalgorithmics S.A. (MDG. WSE) is a global healthcare technology company specializing in AI-based cardiac diagnostic and analytic algorithms. Using AI and predictive analytics, the company offers products that enable early detection, precise diagnosis, and comprehensive monitoring of medical abnormalities. These solutions empower customers to provide valuable clinical insights, streamline workflows, and reduce the reliance on human data review.